CTVA · Corteva
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $12.46
Updated ·
Price against the kill line
24.3% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $12.46, set on 12 November 2026. The shares are down 17.1% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $12.46, the 50-day average of adjusted closes as of 11 November 2026, which would show the shares recovering the whole post-report drop and leading. A fourth-quarter report showing Latin American organic sales growth would also prove the call wrong.
Research onlyNot in the portfolio.
Key figures from the filings · Consumer Staples
Quarter to 30 September 2026, filed 12 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 2,458
- Revenue, change on a year (%)
- −6.1
- Gross margin (%)
- 37.6
- Operating margin (%)
- −22.6
- Free cash flow, four quarters ($M)
- −149
- Net cash, cash less debt ($M)
- 475
- Price to earnings (×)
- 8.3
- Enterprise value to sales (×)
- 0.3
All filed numbers
What Corteva reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| filed | 2,458 | −6.1 | 37.6 | −22.6 |
| filed | 6,379 | −1.2 | 57.4 | 27.3 |
| filed | 4,905 | +11.0 | 51.6 | 19.9 |
| filed | 3,910 | −1.7 | 42.4 | 3.5 |
| filed | 2,618 | +12.6 | 37.2 | −13.3 |
| filed | 6,456 | +5.6 | 54.6 | 26.3 |
| Pre-tax income ($M) | −589 |
| Net income ($M) four quarters: 759 | −570 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | −1.6 |
| Operating cash flow ($M) | 427 |
| Capital spending ($M) | 576 |
| Free cash flow ($M) | −149 |
| Cash and short-term investments ($M) | 3,933 |
| Debt ($M) long-term debt | 3,458 |
| Net cash, cash less debt ($M) | 475 |
| Deferred revenue ($M) −7.4% on a year | 561 |
| Backlog, orders not yet delivered ($M) +7.5% on a year | 158 |
| Receivables ($M) | 4,797 |
| Inventory ($M) | 5,482 |
| Shareholders' equity ($M) | 24,493 |
| Market value ($M) | 6,293 |
| Enterprise value, market value plus net debt ($M) | 5,818 |
| Enterprise value to sales (×) | 0.3 |
| Enterprise value to operating income (×) | 2.5 |
| Price to earnings (×) | 8.3 |
| Price to book value (×) | 0.3 |
| Free-cash-flow yield (%) | −2.4 |
Short interest (FINRA, settled 15 October 2026, published 13 November 2026): 5.8% of shares outstanding sold short, 1.0 days of average trading to cover, +78.3% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $636K |
The thesis
Corteva is more likely to trail the S&P 500 over the next three months. On 11 November 2026 it reported its first quarter as a stand-alone crop-protection company, and it cut its 2026 profit outlook because Brazil "was materially weaker than anticipated," in the words of Chief Executive Luke Kissam. The fourth-quarter report, expected in early February 2027, settles whether Latin America stabilises and what the first stand-alone outlook for 2027 looks like.
The rating is Low because the cut comes in the company's most important selling season. The causes the company names do not look like one-quarter problems: farmer cash shortages and costly credit in Brazil, distributors buying only as needed, and price competition on older products. Year-to-date adjusted operating earnings per share (EPS) through September were $0.76. The new full-year range is $0.76 to $0.80, so the bottom of the range is already reached and the fourth quarter adds little.
The market priced the cut in one session. The shares closed at $12.14 on 11 November 2026, before the report, and traded down 23% at $9.40 during the 12 November 2026 session, according to Proactive Investors. That price already assumes a smaller 2026 base. It does not yet reflect a reset 2027 outlook, which the company has not given.
Bullish and bearish views on Corteva, Inc.
The bull case on Corteva, Inc. (CTVA), in brief: new products are still growing fast. The bear case: Latin America is in sharp decline.
Bull case
- New products are still growing fast. New crop-protection products grew 20% in the third quarter across all regions, led by Arylex and Pyraxalt, and new-product volume rose 14% year to date (Q3 2026 presentation, 12 November 2026).
- Outside Latin America, sales grew. North American sales rose 7% to $574 million on 19% higher volume. Sales in Europe, the Middle East and Africa rose 12% to $239 million, and Asia Pacific rose 3% to $208 million (8-K results release, 11 November 2026).
- Nine-month margins held up. Year-to-date adjusted pro forma operating EBITDA (earnings before interest, taxes, depreciation and amortisation) was $943 million, flat on the prior year, and the margin rose 30 basis points to 17.6% (8-K, 11 November 2026).
- The board authorised a dividend and a cost program. The board authorised the first common dividend since the spin-off but did not state an amount. The company expects $130 million to $140 million of pre-tax restructuring charges in 2026, with the program substantially complete in 2028 (8-K, 11 November 2026).
Bear case
- Latin America is in sharp decline. Latin American sales fell 28% to $570 million in the third quarter. Organic sales fell 31%, on 24% lower volume and 7% lower prices (8-K, 11 November 2026).
- Pricing fell in two big regions. Total third-quarter price fell 7% and volume 2%, for net sales of $1.591 billion, down 9%. The company cites U.S. acetochlor pricing and competition on molecules late in their life cycle in Latin America (8-K, 11 November 2026).
- The quarter missed by a wide margin. Operating EPS of $0.06 fell 57% and missed the $0.10 consensus. Revenue of $1.59 billion missed the $1.76 billion estimate (Proactive Investors, 12 November 2026).
- The 2026 outlook fell well short of expectations. Full-year adjusted pro forma operating EBITDA guidance is $1.100 billion to $1.125 billion, a 12% decline at the midpoint (Investing.com, 12 November 2026). The $0.76–$0.80 EPS range compares with a $1.07 consensus, according to news reports on 11 November 2026.
- Biologicals fell in the quarter. Biologicals sales fell 22% in the third quarter, or 24% on an organic basis (Q3 2026 presentation, 12 November 2026).
- There is legal exposure on an older chemical. A lawsuit over chlorpyrifos was filed against Corteva and The Dow Chemical Company, according to company news on 9 November 2026.
Price setup
Corteva distributed its seed business as Vylor Inc. (NYSE: VYLR) on 1 October 2026, one Vylor share for each Corteva share. Quoted prices before that date are for the combined company. The 52-week intraday high of $90.97 on 29 July 2026 is a pre-spin level and does not compare with today's shares.
Since the spin-off, the shares have traded in a narrow range. The 52-week closing low is $11.33, set on 28 October 2026. The quoted close was $12.26 on 4 November 2026 and $12.14 on 11 November 2026, the last close before the results reaction. On adjusted daily closes, the 50-day moving average was $12.46 and the 200-day was $12.11 as of 11 November 2026, and the three-month change was 7.0%.
The 12 November 2026 session took the shares to about $9.40 intraday, according to Proactive Investors, well below the post-spin closing low of $11.33. If the session closes near that level, the stock sits about a quarter below both moving averages. For the shares to lead from here, they would have to recover the whole post-report drop while the company still has no 2027 outlook. No published analyst target is used here: every target found for the new Corteva dates from before the 11 November 2026 report.
Catalysts ahead
- ~4 February 2027 (est.): Fourth-quarter 2026 report and first stand-alone 2027 outlook. Shows whether Latin American volume and pricing stop falling and sets the first full-year earnings base for the crop-protection company; a 2027 outlook above 2026 would challenge the lag call.
What would change the view
A daily close above $12.46, the 50-day average of adjusted closes as of 11 November 2026, which would show the shares recovering the whole post-report drop and leading. A fourth-quarter report showing Latin American organic sales growth would also prove the call wrong.
What it trades with
Since 1 October 2026, Corteva trades as a pure crop-protection company. Its results now depend on how much farmers spend on chemicals and how easily they can get credit, especially in Brazil, more than on the seed-genetics cycle now carried by Vylor. The Brazilian season makes the fourth quarter and the first quarter the periods where the Latin American decline either repeats or eases.
Insider filings give no signal on value. The SEC Form 4 filings dated 3 November 2026 are director stock grants of 2,792, 2,792 and 666 shares at $11.64 on 30 October 2026. They were awards, not open-market purchases. The September 2026 Form 4s from the chief financial officer and the chief legal officer record shares withheld for tax at pre-spin prices.
Notes
- Corteva spun off its seed business as Vylor Inc. (NYSE: VYLR) on 1 October 2026, one share for one; quoted CTVA prices before that date reflect the combined company.
- Full-year 2026 guidance is stated on an adjusted pro forma basis for the stand-alone crop-protection business, not on reported GAAP figures.
The evidence, claim by claim (7)
- Q3 2026 net sales $1.591B, down 9%; price −7%, volume −2%; operating EBITDA $222M, down 17%; operating EPS $0.06, down 57% Corteva Q3 2026 results release, 8-K · as of
- Latin America Q3 sales $570M, down 28% reported and 31% organic, on volume −24% and price −7% Corteva Q3 2026 results release, 8-K · as of
- Full-year 2026 guidance cut to adjusted pro forma operating EBITDA of $1.100B-$1.125B and operating EPS of $0.76-$0.80, citing Brazil Corteva Q3 2026 results release, 8-K · as of
- Year-to-date operating EPS through Q3 2026 was $0.76; adjusted pro forma operating EBITDA $943M, flat, margin 17.6% Corteva Q3 2026 results release, 8-K · as of
- Q3 operating EPS of $0.06 missed the $0.10 consensus; revenue of $1.59B missed the $1.76B estimate Proactive Investors, 12 November 2026 · as of
- Crop protection new products grew 20% in Q3; biologicals sales fell 22% reported, 24% organic Corteva Q3 2026 earnings presentation · as of
- Seed business distributed as Vylor Inc. (NYSE: VYLR), one share per Corteva share; Corteva kept the CTVA ticker Vylor spin-off completion report, Pulse 2.0 · as of
Sources
- Corteva, Inc. - Form 8-K - FY2026 · sec.gov ·
- Corteva shares plunge 23% as earnings miss and weaker Brazil demand force guidance cut · proactiveinvestors.com ·
- Corteva crop protection Q3 2026 slides reveal Brazil challenges · investing.com ·
- Vylor Completes Corteva Spin-Off And Begins Trading On NYSE · pulse2.com